Amendment 1: • Address changes based on feedback from the Food and Drug Administration (FDA). • Target population was amended per FDA request. • Eligibility criteria was amended per FDA request. • The information related to dose limiting toxicity was amended per FDA request. • Study stopping rules based on a specified rate of unacceptable toxicity were added per FDA recommendation. • Inclusion criteria pertaining to previous lines of therapy for MM were amended per FDA request. • Exclusion criteria pertaining to dose of prednisone was amended per FDA request. • The information on route of administration of daratumumab was modified to provide clarity. • The information on dose modification and delays of magrolimab was modified to provide more clarity. • The information on bone marrow assessments was modified to provide more clarity. • The text on management of infusion related reactions was modified to provide more clarity. • New section on ‘Management of Pneumonitis’ was added per FDA request. • New section on ‘Management of Other Non-hematologic Adverse Events’ was added per FDA request. • The text on formulations of daratumumab was modified to provide more clarity. • The text toxicity management of pomalidomide was modified to provide more clarity. • The text for referring applicable product’s label for bortezomib was added. • New references were added for ‘Treatment-Related Toxicity monitoring’. • X added to line for Urine Immunofixation (UIFE), for consistency with Section 6.5.1 of the protocol. • The schedule of assessments (SOA) table was updated to specify peripheral smear separately. • Antidrug antibody sampling once in 12 weeks (Q12W) was removed from table.

Amendment 2: • Changes to inclusion criteria #11: Updated to mitigate against a drop in hemoglobin with the initial dosing of magrolimab. Changes to inclusion criteria #22 and #25, and removal of inclusion criteria #21, #24, and #28: Updated based on feedback from external experts in the field of multiple myeloma in order to select appropriate patients for the study. Addition of inclusion criteria #21: Updated to ensure consistency with inclusion criteria for other combination arms. • Study Schema was updated to include 3 prior therapies, in line with Amendment 1. • Information related to time interval between completion of magrolimab infusion/injection and the initiation of daratumumab was removed. Daratumumab should be given before magrolimab with a 1 hour observation period in between. • Information on magrolimab discontinuation was amended per FDA request. • Corrected an error. Updated dosing duration in line with USPI for dosing days and cycle length for dose reductions.

Amendment 3: • Text was added to allow use of approved generic or a biosimilar for combination agents. • New section was added to provide a description and summary of clinical data for carfilzomib. • The description of bortezomib was updated to remove redundant text that was added to a previous section. • Text was added to add a rationale for carfilzomib as the preferred proteasome inhibitor. • Study schema was updated to add carfilzomib as the preferred proteasome inhibitor. • The section 3.1.1. Safety Run-in Cohorts was updated to remove the need for additional safety follow-up evaluation based on the updated Cycle 3 dose for magrolimab. • Text updated to section 3.8.2. Pharmacokinetics/Biomarker Samples for Optional Future Research to include buccal samples. • Inclusion criteria was updated to indicate requirements for previous lines of therapy for patients. • Inclusion criteria were updated to add requirements for previous lines of therapy for patients who will receive magrolimab in combination with daratumumab. • Inclusion criteria were updated to add requirements for previous lines of therapy for patients who will receive magrolimab in combination with pomalidomide and dexamethasone. • Inclusion criteria were updated to add requirements for previous lines of therapy for patients who will receive magrolimab in combination with carfilzomib and dexamethasone. • Inclusion criteria were updated to add criteria for patients who will receive magrolimab in combination with bortezomib and dexamethasone. • Exclusion criteria was added to exclude patients who received any live vaccine within 4 weeks prior to treatment. • Text was updated to expand description of physical appearance of magrolimab. • New section was added to include a description of the formulation, packaging and labeling, and storage and handling of carfilzomib. • Text was updated to add a window for magrolimab dosing.

Amendment 3: • New section was added to give instructions for dosage and administration of carfilzomib and dexamethasone. • Text was added to Magrolimab section to give guidance regarding dose delays and interruptions for the combination drugs. • Table 11 was updated to reflect new dosing regimen for magrolimab from Cycle 3 onwards. • Text was deleted to update guidance regarding dose delays and interruptions of daratumumab. • Text was updated to add recommendations for carfilzomib dose modifications and delays based on toxicity. • Text was added to clarify that live vaccines are prohibited before and during the study. • Table was updated to clarify prohibited prior medications for drug combinations with magrolimab. • Text added to clarify allowance of COVID-19 vaccines. • Text was revised to clarify type and screen procedures. • Text was updated to give instructions for toxicity management for carfilzomib. • The section was added to give instructions for toxicity management for carfilzomib. • The appendix was updated to include guidance for pregnancy and contraception for carfilzomib.

Amendment 4: • Inclusion Criterion #10 (Section 4.2) was updated to indicate that hemoglobin level must be ≥ 9 g/dL prior to initial dose of study treatment. • Inclusion Criterion #11 (Section 4.2) was removed as there is no added clinical advantage of necessitating a hemoglobin threshold of 9.5 g/dL or more in patients with cardiac comorbidities. • Inclusion Criterion #20 (Section 4.2) was updated to remove the requirement for patients to have CD38-positive multiple myeloma. • Additional clarification on timing of magrolimab premedication was added to Section 5.3.1. • Type and Screen and Direct Antiglobulin Test (Section 6.2.2) was updated to remove details from this section and refer to Section 7.8.1.1. • Dosage and Administration of Magrolimab (Section 5.3.1) and Laboratory Assessments (Section 6.4.2) were updated to link to the hemoglobin monitoring and testing requirements detailed in Section 7.8.1.1. • Anemia management described in Anemia, Blood Cross-matching, and Packed Red Blood Cell Transfusion Procedures (Section 7.8.1.1) and its subsections was updated to clarify the risk of anemia in the first 2 weeks of treatment and provide additional guidance for enhanced anemia management. Updates include adding the requirement to confirm hemoglobin level prior to magrolimab dosing and within 24 hours after the first 2 doses of magrolimab. • Thromboembolic Events (Section 7.8.1.3) text was added to match the investigator’s brochure (IB) Edition 9. • Hemagglutination and Microangiopathy text was deleted from Section 7.8.1.3 Toxicity Management to match the IB Edition 9. • Text was updated to align the publications language in the clinical trial agreement (Section 9.2.2).

Amendment 4: • Appendix 10 was added to include the Myeloma Frailty Score Calculator Additional change(s) to the protocol include the following: • Administrative, editorial, and formatting updates, changes, corrections, and clarifications were made throughout, where appropriate, including section numbering and references. • Changes in the body of the protocol were also updated in the synopsis and study procedures tables, as appropriate.

Amendment 5: • Lowered the stopping boundary due to toxicity from greater than 33% to greater than 25% of patients experiencing a Grade 4 or higher treatment related AE (Section 3.1.3; Table 3) in order to increase patient safety during the dose expansion phase of the study. • Clarified the process for analyzing bone marrow samples during screening. (Section 6.2). • Clarified the processes for investigator evaluation of disease response assessments by providing additional detail regarding which assessments would be analyzed at the central laboratory versus locally (Section 6.5.2 and 6.5.4).

Amendment 6: • Removal of posttreatment follow-up for disease progression and survival follow-up assessments and secondary endpoints for progression-free survival (PFS) and overall (OS) as efficacy data will no longer be collected after the end-of-treatment (EOT) visit. • Removal of exploratory endpoint for minimal residual disease (MRD) negativity rate as central laboratory assessment of MRD is no longer required. • Removal of exploratory endpoints/analyses to evaluate the association of each biomarker or combination of biomarkers with clinical outcomes as there are no plans to perform these analyses anymore. • Guidance for the use of corticosteroids as premedication for the first few infusions of magrolimab has been incorporated to align with the information in Edition 12 of the Investigator’s Brochure. • Clarification of standard of care procedure language incorporated from Administrative Amendment 1 for Protocol Amendment 5. • Removal of receptor occupancy assessment. • Removal of the requirement for multiple myeloma, tumor response, and bone marrow assessments to be performed by a central laboratory. These assessments may now be performed by a central or local laboratory based on investigator preference. • Removal of FACT-MM questionnaire assessment as patient-reported outcome data are no longer required. • Guidance for the management of infusion-related reactions has been updated to incorporate the use of corticosteroids as premedication during the first few infusions of magrolimab, and to incorporate guidance for discontinuation of magrolimab in certain cases. This was done to align with the information in Edition 12 of the Investigator’s Brochure. • Toxicity management section for magrolimab has been updated to include guidelines for dose delay and discontinuation in case of severe neutropenia and serious infections to align with the information in Edition 12 of the Investigator’s Brochure.

Amendment 6: • Clarification that assessment of quantitative Ig levels is to be performed for patients with IgA and IgD myelomas to align with Section 6.5.1. • Contraception appendix has been updated to reflect the latest nonclinical embryo-fetal development toxicity data. • Global Patient Safety (GLPS) has been updated to Patient Safety (PS) to reflect the new department name.